Abstract
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.
Original language | English (US) |
---|---|
Pages (from-to) | 329-332 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 59 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2012 |
Externally published | Yes |
Keywords
- Developmental therapeutics
- JNJ-26854165
- Preclinical testing
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology